Table 2.

Antiproliferative activity of mAbs with and without cross-linking


Antiproliferative activity of mAbs

Rituximab + hL243γ4P

Rituximab (P)

hL243γ4P (P)
Without cross-linking    
   Ramos   18.2 ± 4.9   –7.9 ± 3.6 (.001)   10.1 ± 11.9 (.362)  
   FSCCL   75.9 ± 10.2   13.4 ± 12.3 (.003)   78.9 ± 1.7 (.661)  
   Namalwa   50.1 ± 1.1   13.8 ± 5.6 (.006)   27.8 ± 3.3 (.004)  
In the presence of antihuman second antibody    
   Ramos   69.0 ± 7.0   50.5 ± 9.4 (.052)   56.8 ± 0.8 (.007)  
   FSCCL   94.5 ± 0.9   28.1 ± 9.6 (.007)   94.5 ± 0.8 (.998)  
   Namalwa
 
58.1 ± 2.1
 
14.7 ± 7.0 (.005)
 
51.5 ± 3.0 (.042)
 

Antiproliferative activity of mAbs

Rituximab + hL243γ4P

Rituximab (P)

hL243γ4P (P)
Without cross-linking    
   Ramos   18.2 ± 4.9   –7.9 ± 3.6 (.001)   10.1 ± 11.9 (.362)  
   FSCCL   75.9 ± 10.2   13.4 ± 12.3 (.003)   78.9 ± 1.7 (.661)  
   Namalwa   50.1 ± 1.1   13.8 ± 5.6 (.006)   27.8 ± 3.3 (.004)  
In the presence of antihuman second antibody    
   Ramos   69.0 ± 7.0   50.5 ± 9.4 (.052)   56.8 ± 0.8 (.007)  
   FSCCL   94.5 ± 0.9   28.1 ± 9.6 (.007)   94.5 ± 0.8 (.998)  
   Namalwa
 
58.1 ± 2.1
 
14.7 ± 7.0 (.005)
 
51.5 ± 3.0 (.042)
 

Numbers represent percent inhibition of 3H-thymidine uptake, and those in parentheses represent P values of the single mAbs compared with the combination of rituximab and hL243γ4P

or Create an Account

Close Modal
Close Modal